The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 428 members (net increase of 97 new members since 2003) from 55 departments based at 3 geographical sites (Rochester, MN - MCR;Jacksonville, FL - MCF;and Phoenix/Scottsdale, AZ - MCA). The goal of the MCCC is to provide the best cancer care today, while developing improved strategies for tomorrow, serving cancer patients throughout the U.S. and the world. MCCC has 12 research programs: Women's Cancer;Gastrointestinal Cancer;Prostate Cancer;Hematologic Malignancies;Neuro-oncology;Cancer Imaging;Cell Biology;Developmental Therapeutics;Immunology &Immunotherapy;Gene &Virus Therapy;Genetic Epidemiology &Risk Assessment;Cancer Prevention &Control. Research is facilitated by 15 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Tissue &Cell Molecular Analysis, Biospecimens Accessioning &Processing, Clinical Research Office;Transgenic &Gene Targeted Mouse Shared Resource, Protein Chemistry &Proteomics, Flow Cytometry/Optical Morphology, Electron Microscopy, Pharmacology, Gene &Virus Therapy, Cytogenetics, and Gene Analysis. Since the last renewal, MCCC has continued to grow with an increase in overall peer-reviewed funding from $77.6 million to $105.8 million and an increase in NCI funding from $56.3 million to $75.7 million. Of particular note is that, in addition to an increase in investigator-initiated grants, MCCC has 2 new SPOREs (Breast and Brain) and 2 new training grants. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Prostate, Multiple Myeloma, Pancreas), as well as several multidisciplinary (P01, N01, 2 U01s, and 2 U10s) and 4 training grants. Research productivity is demonstrated by a 28% increase in annual publications during this period, particularly high impact clinical and scientific publications. Since the last competitive renewal, MCCC has benefited from: 1) new facilities with a net increase in new lab space (>100,000 sq ft) as well as new inpatient / outpatient space;2) increased institutional commitment with a) 11 new endowed professorships ($22M institutional / $22M philanthropic), b) salary/start-up funds for 15 new faculty, c) funds to enhance integration of MCCC across 3 sites ($7.6M), and d) funds to enhance accrual of underserved minorities to clinical trials at MCA and MCF ($13M over 5 years). During the past 5 years, Developmental Funds from CCSG have been leveraged to aid in faculty recruitment at each of the 3 sites. During the next 5 years, we have plans to expand genetics, lung cancer, and melanoma research.

Public Health Relevance

The Mayo Clinic Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted within Mayo Clinic. The Center's goal is to translate the discoveries in the laboratory into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-38S2
Application #
8533253
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$36,297
Indirect Cost
$13,469
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications